FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Scholar Rock announced the FDA issued a Complete Response Letter (CRL) for its Spinal Muscular Atrophy (SMA) treatment, apitegromab, solely due to observations at the Catalent Indiana LLC fill-finish facility, now owned by Novo Nordisk. No other approvability issues were cited, and Scholar Rock intends to resubmit the Biologics License Application (BLA) upon resolution of these facility-related concerns. This delay impacts the availability of apitegromab, which is the first muscle-targeted SMA treatment to demonstrate clinical success in a pivotal Phase 3 trial and holds multiple expedited designations.

Analysis

Scholar Rock (SRRK) has experienced a significant regulatory setback with the receipt of a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for apitegromab. Critically, the CRL is exclusively related to manufacturing observations at a third-party fill-finish facility in Indiana, now owned and operated by Novo Nordisk (NVO), and not due to any deficiencies in the drug's clinical data, safety, or efficacy. The FDA cited no other approvability issues for apitegromab, a first-in-class, muscle-targeted treatment for Spinal Muscular Atrophy (SMA) that has demonstrated success in a pivotal Phase 3 trial and holds multiple expedited designations, including Priority Review. This development delays the potential market entry of a highly anticipated therapy, shifting the timeline for approval to an uncertain future date dependent on Novo Nordisk's successful remediation of the facility's issues. While this news is negative for Scholar Rock's commercialization timeline, the integrity of the apitegromab asset itself remains unchallenged by the regulator, a crucial distinction for assessing the company's long-term prospects.

Key Decisions for Investors

• Investors in Scholar Rock should monitor for updates from both SRRK and Novo Nordisk regarding the remediation timeline for the Indiana manufacturing facility, as this is now the primary gating item for the BLA resubmission and subsequent approval.
• While the CRL introduces near-term uncertainty and stock price pressure for SRRK, the lack of clinical or safety issues could represent a dislocation for long-term investors, as the fundamental value proposition of apitegromab appears intact pending resolution of the third-party manufacturing issue.
• This event flags an operational risk for Novo Nordisk concerning its newly acquired facility, which could have implications for other products dependent on this site; for Catalent (CTLT), the impact is neutral as it no longer owns or operates the facility in question.